Shares of LeMaitre Vascular Inc. (NASDAQ:LMAT) rose 3.4% on Tuesday . The stock traded as high as $17.82 and last traded at $17.81, with a volume of 79,988 shares. The stock had previously closed at $17.22.

LMAT has been the subject of several recent analyst reports. Brean Capital raised their price objective on shares of LeMaitre Vascular from $17.50 to $20.00 and gave the stock a “buy” rating in a report on Thursday, July 28th. Canaccord Genuity set a $19.00 price target on shares of LeMaitre Vascular and gave the company a “buy” rating in a report on Thursday, July 28th. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a report on Thursday, May 5th. Roth Capital raised their price target on shares of LeMaitre Vascular from $18.00 to $18.50 and gave the company a “buy” rating in a report on Tuesday, May 3rd. Finally, Barrington Research raised their price target on shares of LeMaitre Vascular from $18.50 to $20.00 and gave the company an “outperform” rating in a report on Thursday, July 28th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. LeMaitre Vascular has a consensus rating of “Buy” and an average price target of $18.72.

The stock’s 50-day moving average price is $14.96 and its 200 day moving average price is $14.83. The firm has a market cap of $328.03 million and a PE ratio of 35.78.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Wednesday, July 27th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.03. The business earned $22.40 million during the quarter, compared to the consensus estimate of $21.59 million. LeMaitre Vascular’s quarterly revenue was up 12.6% on a year-over-year basis. Equities analysts predict that LeMaitre Vascular Inc. will post $0.55 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Monday, August 22nd will be issued a dividend of $0.045 per share. This represents a $0.18 dividend on an annualized basis and a dividend yield of 1.01%. The ex-dividend date is Thursday, August 18th.

In other news, insider David B. Roberts sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $17.63, for a total transaction of $176,300.00. Following the completion of the sale, the insider now owns 140,493 shares of the company’s stock, valued at approximately $2,476,891.59. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Peter R. Gebauer sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $16.47, for a total transaction of $494,100.00. Following the sale, the insider now directly owns 25,374 shares of the company’s stock, valued at approximately $417,909.78. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in LeMaitre Vascular stock. Cornerstone Capital Management Holdings LLC. boosted its position in LeMaitre Vascular Inc. (NASDAQ:LMAT) by 337.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,289 shares of the company’s stock after buying an additional 49,589 shares during the period. Cornerstone Capital Management Holdings LLC. owned approximately 0.35% of LeMaitre Vascular worth $1,109,000 as of its most recent filing with the SEC.

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.